Skip to Content
  • Previous Rank86
  • Revenues ($M)$30,390
  • Revenue Percent Change-6.9%
  • Profits ($M)$13,501
  • Profits Percent Change-25.4%
  • Assets ($M)$56,977
  • Employees9,000
  • Market Value — as of March 31, 2017 ($M)$88,788

Gilead is known for its hepatitis C cures Sovaldi and Harvoni. But backlash to those drugs’ prices (among other problems) has contributed to the biotech giant’s 2016 slump. Gilead revenues fell nearly 7% to $30.4 billion in 2016 compared to the previous year. Some analysts have been urging the drug maker to make a major acquisition to shore up its experimental pipeline; but Gilead appears determined to invest in its own drug candidates by pumping money into R&D. And, in the meantime, it’s sitting on a massive bed of cash.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

John F. Milligan
CEO Title
President, Chief Executive Officer & Director
Health Care
HQ Location
Foster City, CA
Years on Fortune 500 List9

Gilead Sciences Rank History

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$30,390-6.9%
Profits ($M)$13,501-25.4%
Assets ($M)$56,977-
Total Stockholder Equity ($M)$18,887-
Market Value — as of March 31, 2017 ($M)$88,788-

Profit Ratios

Profit as % of Revenues44.4%
Profits as % of Assets23.7%
Profits as % of Stockholder Equity71.5%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)9.94
EPS % Change (from 2015)-16.5%
EPS % Change (5 year annual rate)41.1%
EPS % Change (10 year annual rate)-

Total Return

Total Return to Investors (2016)-27.6%
Total Return to Investors (5 year, annualized)29.4%
Total Return to Investors (10 year, annualized)16.4%